Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0599 in early Parkinson's disease
NL-OMON52354Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of minzasolmin in Parkinson's disease (PD) (3 arms), sponsored by UCB. Primary endpoints: Clinical symptoms of disease progression over 12 and 18 months and Safety and tolerability. Started Sep 2021; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON52354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52354.